Zai Lab
Karl Hsu is a seasoned professional in global drug development, particularly in the hematology and oncology sectors. Currently serving as Senior Vice President of Clinical Research and Early Development at Zai Lab since April 2020, Karl leads various development functions and has extensive experience in early development, clinical pharmacology, and translational medicine. Prior to this, Karl held significant positions at Sanofi, including Head of Oncology Development Strategy and Science and Associate Vice President, Global Head of Early Development Oncology, where responsibilities encompassed global development strategies within oncology. Karl's earlier career included key roles at Merck as Director of Clinical Oncology, focusing on clinical trials, and academic positions at Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center. Karl completed medical education at the University of Pennsylvania School of Medicine and holds a BA in Biochemistry from Case Western Reserve University.
This person is not in any teams
This person is not in any offices
Zai Lab
5 followers
Zai Lab Ltd is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.